Cargando…
Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 (+) CD8 (+) T cells in HCC via blocking VEGFR2
Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1(+) CD8(+) T cells in HCC microenvironment have not been systematically studied. Here, we established an orth...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067412/ https://www.ncbi.nlm.nih.gov/pubmed/36609997 http://dx.doi.org/10.1111/cas.15719 |